Key result
Treatment with concurrent proton beam therapy and paclitaxel followed by adjuvant chemotherapy resulted in complete remission and a disease-free survival of 26 months in a patient with right atrial cardiac angiosarcoma and R1 resection.
Why the study?
Cardiac angiosarcoma is a rare malignancy with an aggressive course and poor prognosis, and standard or more radical approaches yield minimal survival improvement with high morbidity.
Does concurrent proton beam therapy and paclitaxel followed by adjuvant chemotherapy improve survival in a patient with right atrial cardiac angiosarcoma after R1 resection?
Population
One 26-year-old man with right atrial cardiac angiosarcoma after R1 resection
Comparison
Concurrent paclitaxel and proton beam therapy followed by adjuvant gemcitabine and docetaxel
Design
Case report
Follow-up
26 months since surgery
Authors
Loading...
May extend DFS after R1 resection in right atrial angiosarcoma; hypothesis-generating and requires prospective validation.
Case Report (n=1)
No
Does concurrent proton beam therapy and paclitaxel followed by adjuvant chemotherapy improve survival in a patient with right atrial cardiac angiosarcoma after R1 resection?
Concurrent proton beam therapy and paclitaxel followed by adjuvant chemotherapy may provide prolonged disease-free survival in patients with right atrial cardiac angiosarcoma undergoing R1 resection.
Mangla et al. (2021) conducted a case report in Right atrial cardiac angiosarcoma (n=1). Concurrent proton beam therapy and paclitaxel was evaluated on Disease-free survival / Complete remission. Treatment with concurrent proton beam therapy and paclitaxel followed by adjuvant chemotherapy resulted in complete remission and a disease-free survival of 26 months in a patient with right atrial cardiac angiosarcoma and R1 resection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: